A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Overview

This is an open-label, multicenter, Phase 1/2 study to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

SparkCures ID 1079
Trial Phase Phase 1/2
Enrollment 215 Patients
Treatments
Tags
Trial Sponsors
  • Celgene Corporation
NCT Identifier

NCT03989414
ACCEPTING

This trial is currently open and accepting patients.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
  2. Relapsed or refractory subjects must have measurable disease and have documented disease progression during or after their last anti-myeloma regimen.
  3. Newly diagnosed subjects must have documented diagnosis with previously untreated symptomatic multiple myeloma.
  4. Females of childbearing potential (FCBP) and male subjects must agree with the pregnancy prevention plan.

Exclusion Criteria:

  1. Subject has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis.
🤔 Am I Eligible?

Understanding this criteria can be difficult - call us today.

(888) 828-2206 Create My Account

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Verified Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine
Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

Winston-Salem, NC

Verified Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University

Atlanta, GA

Verified John Theurer Cancer Center Hackensack Meridian Health
John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

SparkCures Verified Accurate, up-to-date information. Learn more

Colorado Blood Cancer Institute Presbyterian/St. Luke's Medical Center (HealthONE)

Denver, CO

Northwestern University Feinberg School of Medicine

Chicago, IL

Massachusetts General Hospital

Boston, MA

Dana-Farber Cancer Institute

Boston, MA

Beth Israel Deaconess Medical Center

Boston, MA

Barbara Ann Karmanos Cancer Institute Wayne State University

Detroit, MI

Mayo Clinic (Rochester)

Rochester, MN

The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute

Columbus, OH

Sarah Cannon TriStar Centennial Medical Center

Nashville, TN

Swedish Cancer Institute Cherry Hill Campus

Seattle, WA

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Moffitt Cancer Center Magnolia Campus

Tampa, FL

University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

MD Anderson Cancer Center The University of Texas

Houston, TX

Colorado
Colorado Blood Cancer Institute Presbyterian/St. Luke's Medical Center (HealthONE)

Denver, CO

  • Recruiting
Florida
Moffitt Cancer Center Magnolia Campus

Tampa, FL

  • Not Yet Recruiting
Georgia
Verified Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University

Atlanta, GA

  • Recruiting

SparkCures Verified Accurate, up-to-date information. Learn more

Illinois
Northwestern University Feinberg School of Medicine

Chicago, IL

  • Recruiting
University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

  • Not Yet Recruiting
Massachusetts
Massachusetts General Hospital

Boston, MA

  • Recruiting
Dana-Farber Cancer Institute

Boston, MA

  • Recruiting
Beth Israel Deaconess Medical Center

Boston, MA

  • Recruiting
Michigan
Barbara Ann Karmanos Cancer Institute Wayne State University

Detroit, MI

  • Recruiting
Minnesota
Mayo Clinic (Rochester)

Rochester, MN

  • Recruiting
New Jersey
Verified John Theurer Cancer Center Hackensack Meridian Health
John Theurer Cancer Center Hackensack Meridian Health

Hackensack, NJ

  • Recruiting

SparkCures Verified Accurate, up-to-date information. Learn more

North Carolina
Verified Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine
Wake Forest Baptist Comprehensive Cancer Center Wake Forest School of Medicine

Winston-Salem, NC

  • Recruiting

SparkCures Verified Accurate, up-to-date information. Learn more

Ohio
The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute

Columbus, OH

  • Recruiting
Tennessee
Sarah Cannon TriStar Centennial Medical Center

Nashville, TN

  • Recruiting
Texas
MD Anderson Cancer Center The University of Texas

Houston, TX

  • Not Yet Recruiting
Washington
Swedish Cancer Institute Cherry Hill Campus

Seattle, WA

  • Recruiting

Resources

There are no resources, links or videos to display for this clinical trial.